Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
Rhea-AI Summary
Quantum BioPharma (NASDAQ: QNTM) signed a binding Letter of Intent with Allucent to support a planned Phase 2 clinical trial of Lucid-MS, a first-in-class neuroprotective candidate that inhibits demyelination. The company expects to initiate the trial in Q2 2026, subject to regulatory approvals and final service agreements.
Allucent will provide global site selection, patient recruitment, data management and regulatory support to accelerate execution and preserve data integrity.
Positive
- Binding LOI with Allucent to support Phase 2 operations
- Planned Phase 2 start Q2 2026, subject to approvals
- First-in-class mechanism targeting demyelination (neuroprotection)
- Allucent provides global CNS/MS trial experience and infrastructure
Negative
- Phase 2 initiation contingent on regulatory approvals (delay risk)
- Definitive services agreement not finalized; terms pending
- No clinical efficacy data yet; outcomes uncertain
News Market Reaction – QNTM
In the Mar 30 session, QNTM declined 10.27%, reflecting a significant negative market reaction. Argus tracked a peak move of +25.0% during that session. Argus tracked a trough of -25.6% from its starting point during tracking. Our momentum scanner triggered 38 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.7x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Clinical trial data | Positive | +38.4% | Peer-reviewed publication of controlled clinical trial results for dietary supplement unbuzzd. |
| Oct 02 | Preclinical reports | Positive | +9.5% | Final reports from key toxicity and toxicokinetic studies supporting Lucid-MS Phase 2 plans. |
| Oct 01 | Advisor appointment | Positive | +0.8% | Appointment of renowned MS expert as clinical development advisor for Lucid-MS trials. |
| Aug 11 | Manufacturing deal | Positive | -10.1% | Agreement with CDMO to manufacture oral Lucid-MS formulation for upcoming Phase 2 trial. |
| Aug 05 | Phase 1 results | Positive | -11.6% | Positive Phase 1 MAD trial CSR showing Lucid-MS safety and tolerability in healthy participants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial news for QNTM often has mixed reactions, with some positive updates met by declines, though the average move for this tag is modestly positive.
Over the past year, Quantum BioPharma has steadily advanced Lucid-MS through preclinical and early clinical milestones. Events from Aug 2025 to Oct 2025 covered Phase 1 MAD safety results, manufacturing for the oral formulation, advisor appointments, and key toxicity and toxicokinetic reports supporting an IND and Phase 2 planning. A Mar 23, 2026 clinical publication on unbuzzd also drove a strong positive move. Today’s Phase 2-focused LOI builds directly on this sequence of Lucid-MS development steps.
Key Terms
clinical trial medical
multiple sclerosis medical
demyelination medical
neuroprotection medical
contract research organization technical
CRO technical
central nervous system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting Demyelination
TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has entered into a binding Letter of Intent (LOI) with Allucent, a global contract research organization with extensive experience supporting central nervous system clinical trials, to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis (MS).
This strategic partnership represents a significant milestone in Quantum BioPharma's clinical development pipeline and underscores the Company's commitment to advancing a potentially innovative solution for those MS patients suffering from debilitating mobility conditions unlike any solution in the market today.
The planned Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with MS. Quantum BioPharma expects to initiate the Phase 2 trial in the second quarter of 2026, subject to regulatory approvals and finalization of the clinical trial design and operational arrangements.
Under the terms of the LOI, Allucent will provide comprehensive clinical trial services designed to support efficient execution and data integrity throughout the study:
| Study Start-Up | Regulatory submissions, ethics approvals | Accelerated trial initiation |
| Site Selection & Management | Global site network coordination | Optimal patient access |
| Patient Recruitment | Enrollment strategy and execution | Efficient trial completion |
| Data Management | Collection, analysis, reporting | Rigorous clinical data integrity |
| Regulatory Support | Agency interactions, compliance | Streamlined development pathway |
The parties will finalize a more comprehensive and definitive services agreement in the coming weeks, solidifying this strategic partnership.
First-in-Class Potential Therapeutic Innovation for MS
Lucid-MS is designed to provide neuroprotection through the inhibition of demyelination—a key driver of disease progression in MS. This innovative mechanism represents a differentiated therapeutic approach in the global MS market, where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration.
“Lucid-MS is a First-in-Class, New Chemical Entity, Therapeutic Innovation designed to provide neuroprotection through the inhibition of demyelination, a key driver of disease progression in MS,” said Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum BioPharma. “This innovative mechanism represents a differentiated therapeutic approach in the global MS market where an estimated 2.8 million people suffer and where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration. This Phase 2 trial will evaluate efficacy, safety and tolerability, while exploring the relationship between this mechanism and established clinical and radiographic markers of disease activity.”
“We are pleased to engage Allucent, a global CRO with extensive experience in Phase 2 and Phase 3 central nervous system trials, including prior MS studies, as we advance our clinical program,” said Zeeshan Saeed, CEO of Quantum BioPharma. “Their therapeutic expertise and global operational capabilities are expected to support the efficient execution of our Phase 2 trial. Our research continues to demonstrate the potential of this novel approach to transform MS patient outcomes.”
Why Allucent: Global CRO Excellence
Allucent is a global, specialty contract research organization designed for small and mid-sized biopharma, delivering integrated clinical, regulatory, and operational expertise across complex programs, including neuroscience. Their proven track record in CNS and MS trials makes them an ideal partner for advancing Lucid-MS through Phase 2.
| Deep CNS/MS Trial Experience | Disease-specific expertise |
| Global Operational Footprint | Access to diverse patient populations |
| Integrated Strategy & Execution | Efficient program delivery |
| Regulatory Excellence | Streamlined agency interactions |
| Data Management Rigor | High-quality clinical evidence |
“We’re proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis,” said Paula Brown Stafford, CEO of Allucent. “Our team brings deep experience in CNS and MS trials, along with an integrated model that aligns strategy and execution, helping ensure programs are delivered efficiently and with the rigor these complex studies demand.”
Market Opportunity and Growth Strategy
Multiple sclerosis affects approximately 2.8 million people worldwide (source: https://pmc.ncbi.nlm.nih.gov Atlas of MS, Third Edition (PMC/NCBI)), representing a significant global healthcare challenge and substantial market opportunity for innovative treatments. The MS therapeutic market is projected to exceed
Quantum BioPharma's differentiated approach—targeting demyelination directly—positions Lucid-MS to address current unmet patient needs and potentially capture meaningful market share in the emerging neuroprotective segment.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of
About Allucent
Allucent is a global, specialty CRO designed for small and mid-sized biopharma, delivering integrated clinical, regulatory, and operational expertise across complex programs, including neuroscience. Visit www.Allucent.com for more information.
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (416) 854-8884
Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com
A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a869efcb-3a0d-4fdc-994f-d7a71596a887
